Suven Life Sciences Limited announced the outcome of its Board of Directors meeting held on July 08, 2026. The board approved the conversion of 1,85,70,133 fully paid warrants into equity shares, allotting an equal number of equity shares of Rs. 1/- each at an issue price of Rs. 134/- per share on a preferential basis. The total consideration received for this allotment amounts to ₹248,83,97,822. Consequently, the company's paid-up equity share capital has increased to ₹28,25,62,686, comprising 28,25,62,686 equity shares. The meeting also saw the approval for the re-appointment of Dr. Vajja Sambasiva Rao as a Non-Executive Independent Director for a second term of five years, effective from January 21, 2027, to January 20, 2032, subject to shareholder approval at the upcoming Annual General Meeting. Additionally, the company resolved to incorporate a wholly-owned subsidiary, Suven Neurosciences Pte. Ltd., in Singapore, which will be a clinical-stage biopharmaceutical company focused on novel therapeutics for neurological and other disorders. The initial investment in the Singapore subsidiary is planned at USD 100.00 million (approximately ₹833 crore), with a price per share of SGD 1.00. The Board meeting commenced at 11:50 A.M. (IST) and concluded at 12:35 P.M. (IST).
